Mineralys Therapeutics, Inc. (MLYS) Stock Profile — Insider Trades & Financials

Net Income-$32.2M

EPS$-1.94

Market Cap$2.3B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Jon Congleton

CEO & Executive Director

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Founded: 2019
Employees: 76
Headquarters: Radnor, Pennsylvania, United States

⚡

Core Efficiency

ROE?

-4.98%

ROA?

-4.87%

📊

Profitability Ratios

Current Ratio?

43.76

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 11, 2026 (in 124 days)

Annual Report (10-K) — Based on filing pattern

Aug 11, 2026

Predicted10-K

Mar 12, 2026

10-KQ4 20257d after period end

Mar 12, 2026

10-KFY 202571d after period end

Nov 10, 2025

10-QQ3 20257d after period end

Aug 12, 2025

10-QQ2 20255d after period end

May 12, 2025

10-QQ1 20254d after period end

Feb 12, 2025

10-KQ4 20245d after period end

Feb 12, 2025

10-KFY 202543d after period end

Nov 12, 2024

10-QQ3 20248d after period end

Loading company sections...

Mineralys Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness